Analysts’ Recent Ratings Updates for Caris Life Sciences (CAI)

Caris Life Sciences (NASDAQ: CAI) has recently received a number of price target changes and ratings updates:

• 8/8/2026 – Caris Life Sciences was downgraded by Wall Street Zen from “hold” to “sell”.
• 8/7/2026 – Caris Life Sciences had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 8/6/2026 – Caris Life Sciences had its “outperform” rating reaffirmed by Evercore Inc. They now have a $26.00 price target on the stock.
• 8/6/2026 – Caris Life Sciences had its price target raised by BTIG Research from $32.00 to $33.00. They now have a “buy” rating on the stock.
• 7/6/2026 – Caris Life Sciences was given a new $25.00 price target by Evercore Inc.
• 7/2/2026 – Caris Life Sciences had its “buy” rating reaffirmed by BTIG Research. They now have a $32.00 price target on the stock.

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.